AnaptysBio Inc
ANAB
查看详细走势图
49.730USD
+1.830+3.82%
收盘 02/06, 16:00（美东）报价延迟15分钟
1.37B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.82%
5天
+4.89%
1月
+10.00%
6月
+144.13%
今年开始到现在
+2.58%
1年
+241.08%
查看详细走势图
TradingKey AnaptysBio Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
AnaptysBio Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名11/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价64.58。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
AnaptysBio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
AnaptysBio Inc亮点
亮点风险
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
业绩高增长
公司营业收入稳步增长，连续3年增长787.33%
业绩增长期
公司处于发展阶段，最新年度总收入91.28M美元
估值低估
公司最新PE估值-17.64，处于3年历史低位
机构加仓
最新机构持股31.62M股，环比增加0.03%
保罗·都铎·琼斯持仓
明星投资者保罗·都铎·琼斯持仓，最新持仓市值13.87K
分析师目标
根据
13
位分析师
买入
评级
64.583
目标均价
+33.49%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
AnaptysBio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
AnaptysBio Inc简介
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.
公司代码ANAB
公司AnaptysBio Inc
CEOFaga (Daniel R)
网址https://www.anaptysbio.com/
相关品种
